作者机构：
[欧晨; 蒋鹏飞; 姚震; 田野; 王英] Hunan University of Chinese Medicine, Changsha, Hunan Province 410208, China;Department of Ophthalmology, First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan Province 410007, China;Key Laboratory of Traditional Chinese Medicine for Prevention and Treatment of Eye, Ear, Nose and Throat Diseases in Hunan Province, Changsha, Hunan Province 410208, China;[彭俊] Department of Ophthalmology, First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan Province 410007, China, Key Laboratory of Traditional Chinese Medicine for Prevention and Treatment of Eye, Ear, Nose and Throat Diseases in Hunan Province, Changsha, Hunan Province 410208, China;[彭清华] Hunan University of Chinese Medicine, Changsha, Hunan Province 410208, China, Department of Ophthalmology, First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan Province 410007, China, Key Laboratory of Traditional Chinese Medicine for Prevention and Treatment of Eye, Ear, Nose and Throat Diseases in Hunan Province, Changsha, Hunan Province 410208, China
通讯机构：
[Peng, Q.-H.] H;Hunan University of Chinese MedicineChina
作者机构：
[汤钰] Hunan University of Chinese Medicine, Changsha, Hunan 410208, China;Hunan Provincial Key Laboratory for Prevention and Treatment of Ophthalmology and Otolaryngology Diseases with Chinese Medicine, Changsha, Hunan 410208, China;Hunan Provincial Engineering and Technological Research Center for Prevention and Treatment of Ophthalmology and Otolaryngology Diseases with Chinese Medicine and Protecting Visual Function, Changsha, Hunan 410208, China;[彭俊; 姚小磊] Department of Ophthalmology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China;Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian 361102, China
通讯机构：
[Yao Xiao-Lei] D;[Liu Zu-Guo] F;Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian 361102, China<&wdkj&>Xiamen Eye Center of Xiamen University, Xiamen, Fujian 361001, China<&wdkj&>Department of Ophthalmology, The First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, China<&wdkj&>Department of Ophthalmology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China
摘要：
Objective To observe the effects of Sanxue Mingmu Tablets (散血明目片) combined with conbercept on patients with wet age-related macular degeneration (wAMD).Methods A total of 70 patients with wAMD were randomly divided into a treatment group with 35 cases (51 eyes) and a control group with 35 cases (50 eyes). The control group was treated with intravitreal injection of conbercept 0.05 ml once a month for three times. The treatment group was additionally treated with oral Sanxue Mingmu Tablets 2.4 g each time, three times a day for three months. The best corrected visual acuity (BCVA), electroretinogram (ERG) amplitude and latency of a wave and 6 wave of the 2 groups were observed before treatment and 1 month, 2 months, 3 months after treatment. Ultrasound was used to detect the peak systolic short-velocity (PSV), end-diastolic flow (EDV), and resistance index (RI) of the posterior ciliary short arteries in the 2 groups of patients. Optical coherence tomography (OCT) was used to detect the macular foveal thickness (CMT). The postoperative complications and the recurrence of 6 months follow-up after treatment were observed.Results Compared with the previous time point within group, the BCVA in both groups was significantly decreased after 1, 2, and 3 months of treatment (P<0.05). When the amplitudes of a wave and b wave, RI, and CMT were compared at all time point in the 2 groups, the differences were statistically significant (P<0.05). There was a statistically significant difference in the EPG a-wave, b-wave amplitude, RI, and CMT between groups after 1, 2, and 3 months of treatment (P<0.05). Compared with in group before treatment, except for PSV after 1 month in the control group, there was a statistically significant difference in PSV and EDV after treatment for 1, 2, and 3 months between groups (P<0.05). The differences between PSV at 2 and 3 months after treatment and EDV at 1, 2, and 3 months after treatment were statistically significant (P<0.05). Conjunctival hyperemia occurred in 1 eye in the treatment group and 2 eyes in the control group after surgery. There was no significant difference in complications between groups (P>0.05). There were 4 cases (5 eyes) relapsed in the treatment group, with a recurrence rate of 11.11%, and 11 patients (15 eyes) relapsed in the control group, with a recurrence rate of 34.09%. The recurrence rate of the treatment group was lower than that of the control group.Conclusion Sanxue Mingmu Tablets combined with Combercept ophthalmic injection can promote the absorption of retinal exudation and bleeding after wAMD, improve vision, and have a good effect on wAMD.
作者机构：
[Zeng Z.-C.] Hunan University of Chinese Medicine, Changsha, 410208, China;[彭俊] Department of Ophthalmology, First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, 410007, China;[蒋鹏飞; 黎冬冬; 彭清华] Hunan University of Chinese Medicine, Changsha, 410208, China, Department of Ophthalmology, First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, 410007, China
通讯机构：
[Peng, Q.-H.] H;Hunan University of Chinese Medicine, Changsha, China
